ReviewCA: a cancer journal for clinicians2019
The current state of molecular testing in the treatment of patients with solid tumors, 2019.
Review in CA: a cancer journal for clinicians, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 143 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Artificial Intelligence to Help Non-Small Cell Lung Cancer Patients: Measure Lung Cancer Biology and Treatment Response Via Imaging
Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
Who cites it
143 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Circulating miRNAs as biomarkers for the diagnosis in patients with melanoma: systematic review and meta-analysis.Frontiers in genetics · 2024Pooled it
- 2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology.Korean journal of radiology · 2021Guideline
- The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- BET inhibitor suppresses melanoma progressionTheranostics · 2020Pooled it
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.Cancer letters · 2021Trial
- Evaluation of Programmed Death Ligand-1 (PD-L1) and B-cell Lymphoma 2 (BCL2) protein expression using immunohistochemistry in colorectal carcinoma patients from Anbar Governorate.Journal of the Egyptian National Cancer Institute · 2026Article
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.Oncotarget · 2026Article
- Evaluation of the Effects of Nicardipine on Entrectinib Metabolism in vitro and in Rats.European journal of drug metabolism and pharmacokinetics · 2026Article
- Article
- Subtype-specific dependencies and therapeutic opportunities in small cell lung cancer.Science advances · 2026Review
- Consensus Copy-Number Alteration Signatures from Clinical Panels Enable Pan-Cancer Risk Stratification and Therapy Response Association.International journal of molecular sciences · 2026Article
- AI-driven WHO 2021 classification of gliomas based only on H&E-stained slides.Neuro-oncology · 2026Article
- Accessibility to molecular studies in gliomas: a challenge for precision medicine in low-resource countries.Frontiers in oncology · 2026Article
- Neuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives.Cureus · 2026Review
- Metabolic signatures for gastric cancer diagnosis and mechanistic insights: a multicenter study.EMBO molecular medicine · 2025Article
- Article
- Review
- Serous Papillary Adenofibroma Cyst of the Ovary in a Young Woman: Case Report and Literature Review.Life (Basel, Switzerland) · 2025Review
- Patient and Clinician Perspectives on the Communication of Genomic Results in Cancer Care.Cancer medicine · 2025Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The world of molecular profiling has undergone revolutionary changes over the last few years as knowledge, technology, and even standard clinical practice have evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing instead of tumor site of origin. Molecular profiling methodologies have likewise changed such that tests that were performed on patients a few years ago are no longer complete and possibly inaccurate today. As with all rapid change, medical providers can quickly fall behind or struggle to find up-to-date sources to ensure he or she provides optimum care. In this review, the authors provide the current state of the art for molecular profiling/precision medicine, practice standards, and a view into the future ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.